Home > Press > Over 40 Early- to Late-Stage Cardiovascular, Oncology, Orthopedics and Spine, Tissue Engineering, Robotics, Blood Substitute, and Imaging, Among Other
February 27-29, 2008, the Venetian, Las Vegas
Over 40 Early- to Late-Stage Cardiovascular, Oncology, Orthopedics and Spine, Tissue Engineering, Robotics, Blood Substitute, and Imaging, Among Other
NEWPORT BEACH, CA | Posted on January 7th, 2008
Medtech Insight, a division of Windhover Information, Inc. and a leading provider of business information for the medical device industry, has announced that in just over 7 weeks, more than 40 promising early- to late-stage medical device companies seeking funding and/or strategic partnership will present at its "Investment In Innovation (In3) West" conference, being held February 27-29, 2008 at The Venetian Resort-Hotel-Casino in Las Vegas, Nevada. The two-day In3 West event (www.windhover.com/in3west08) - the company's 29th In3 conference - will showcase a total of over 50 innovative young medtech companies from around the world presenting (many for the first time on our stage) to an audience of 250+ senior business development and investment executives from the leading medical technology and healthcare investment firms, for purposes of raising funding or forming strategic partnerships.
Presentations from this group of cutting-edge early- to late-stage companies, carefully selected by our staff and Advisory Board of expert healthcare investment professionals, will encompass a wide variety of high-growth device sectors, including cardiovascular therapeutics and diagnostics/interventional cardiology, diagnostics, drug delivery, imaging, minimally invasive surgery, nanotechnology, neurostimulation, oncology, orthopedics/spine, peripheral vascular, stem cells, stroke management, tissue engineering, and wound management, to mention only a few. Presenters confirmed to date include Angel Medical Systems, Armune BioScience, BioTelligent, Bone Biologics, Cardiac Output Technologies, Ceragenix Pharmaceuticals, Cohera Medical, CoreSpine Technologies, Crospon, Deca-Medics, eCardio Diagnostics, HealthLink Europe, HemoBioTech, Hepgen, Infrared Sciences, Innovent Medical Solutions, Light Sciences Oncology, Minnow Medical, mNemoscience, Moerae Matrix, Nerites, Nesos Health, Photo Dynamic Therapy, PolyRemedy, Portland Orthopaedic, Praxim, Provista Life Sciences, Seno Medical Instruments, Sunshine Heart Company, TheraCardia, ThermopeutiX, Tissue Genetics, Ultimate Spine, ValveXchange, VeinAid, Veran Medical, Victhom Human Bionics, Visualase, Vivoxid, Xylos Corporation, and Zassi Medical Evolutions, among others being added to the program regularly.
The In3 West format will include focused 10-minute presentations by a senior executive from each presenting company to our full audience, each followed immediately by one-on-one meetings with interested parties in private breakout rooms. The event will also feature a presenting company product exhibition/networking reception, a Manufacturer Perspective panel discussion/case study titled "What Are Buyers Looking for in 2008?", a Venture Perspective panel discussion/case study, "Doing Innovative or Unconventional Deals," a workshop presented by Christopher Velis of Medical Capital Advisors entitled "10 Things Every Medical Technology Entrepreneur Should Know," and much more.
Event co-sponsors include AdvaMed, Battelle, Business Wire, Curran International, MDMA, Medmarc and The Hartford, Medical Capital Advisors, The MedTech Group, and Ronald Trahan Associates.
Our growing attendee list includes a robust line-up of buy-side/investors. A sample of companies sending their teams include: 3M, Abbott Laboratories, AstraZeneca Pharmaceuticals, Aubrey Group, Baxter Healthcare, Becton Dickinson & Co., Boston Scientific, C.R. Bard, Clarus Ventures, Ethicon, Ethicon Endo-Surgery, ev3, Frazier Healthcare Ventures, Galen, InterWest Partners, Johnson & Johnson Development, Kimberly-Clark Health Care, Kobayashi Pharmaceuticals of America, Longitude Capital, MedVenture Technology, Musculoskeletal Transplant Foundation, Numenor Ventures, Olympus Medical, Prospect Venture Partners, Sante Ventures, Special Situations Life Sciences Fund, Stryker, SV Life Sciences, SVB Capital, Synergy Life Science Partners, Teijin America, Teijin Pharma, The Integra Group, Triathlon Medical Ventures, and Western Technology Investment, among many others.
Medtech Insight and its parent company, Windhover Information, have established a reputation as holding the premier forums worldwide for discerning senior executives in the medical device, diagnostics, biotech, and pharmaceutical business development and investment communities to meet and screen promising early-stage life sciences companies in need of funding, acquisition and/or strategic partnership, and to network with key decision makers in the industry. Over 1300 emerging medical technology company presenters and over 7000 attendees have participated at In3 events over the past 7 years.
Visit http://www.medtechinsight.com/pastpresenters.html for a full list of previous Medtech Insight conference presenters and their technology descriptions. To read what past attendees and industry experts think of Medtech Insight's investment and partnering events, please visit http://www.medtechinsight.com/in3success.html .
The company's Spring 2008 "Investment In Innovation" event - In3 Europe - will be held in Paris, France at the Hilton Paris, April 29-30. Information on this exciting international medtech investment conference will be posted soon on the Medtech Insight website.
About Medtech Insight
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace.
For more information, please click here
Medtech Insight, a division of Windhover Information Inc.
Kristy Grimes, 480-985-9512
or 888-202-5939 toll-free in the U.S.
Copyright © Business Wire 2008
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nano Labs Shareholder Update March 8th, 2014
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Nano Labs Shareholder Update March 8th, 2014
Squeezing light into metals: University of Utah engineers control conductivity with inkjet printer March 7th, 2014
Up-Converted Radio: The way to treat radio waves in a noisy environment is to turn them into visible light March 7th, 2014
Carbodeon NanoDiamonds PTFE Coating doubles surface durability and reduces friction by up to 66 percent: New surface coating enables cost-effective CO2 and fuel reductions in machinery March 6th, 2014
Singapore's A*STAR IME will present 9 papers in optical device innovation and foundry-qualified platform development at world-class optical communications conference March 6th, 2014
How 19th Century Physics Could Change the Future of Nanotechnology: University of Cincinnati physics researchers have developed a new way of using an old technique that could help build better nanotechnology March 5th, 2014
Malvern Instruments announces guest presenter for March 18th protein characterization webinar: Renowned protein scientist Prof. Dr. John F. Carpenter shows how combining Dynamic Light Scattering with Raman Spectroscopy delivers new insights in protein stability, aggregation... March 4th, 2014
UC research tests which nano system works best in killing cancer cells: New UC research to be presented this week tested four iron-oxide nanoparticle systems to see which, when heated, would likely work best as a tool for targeting cancer cells March 4th, 2014